Bayer, Abbott Billion-Dollar Mass-Tort Risk
Listen now
Description
Companies facing multibillion-dollar exposure from mass-tort personal-injury litigation have faced massive jury verdicts in 2024. In this Votes and Verdicts episode, BI litigation analyst Holly Froum is joined by mass-tort expert and attorney Joseph Fantini to discuss some of the major litigation facing consumer and industrial companies, including cancer claims against Bayer’s Monsanto weedkiller, Zantac lawsuits against drugmakers GSK and others, NEC litigation against Abbott and Reckitt’s Mead Johnson unit and PFAS cases against 3M and other manufacturers. They discuss potential catalysts, the strength of cases, as well as likelihood of potential global settlements. See omnystudio.com/listener for privacy information.
More Episodes
Following Donald Trump’s election victory on Nov. 5, a series of personnel and policy changes at the Federal Trade Commission and Department of Justice could have significant ramifications for the antitrust landscape in the years to come — both in terms of M&A oversight and future enforcement...
Published 11/15/24
President-elect Donald Trump’s Nov. 5 victory is poised to have significant effects on a wide swath of industries, likely helping determine whether banks, drugmakers, health insurers, internet platforms and automakers remain under regulatory pressure or see some relief. Corporate tax rates and...
Published 11/08/24
Published 11/08/24